HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $18.
September 11, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Roivant Sciences and maintained a price target of $18, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a price target at $18 by a reputable analyst suggests positive sentiment and confidence in Roivant Sciences' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100